Radiation Therapy or Observation After Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically or cytologically confirmed non-small cell lung cancer (NSCLC)
• * Mixed histology allowed if all components are consistent with NSCLC
• * Squamous cell histology allowed
• Stage IV disease
• * Oligometastatic disease (M1 with 1-3 metastases)
• * Patients with M1 disease that involves intrapulmonary metastases are eligible provided ≤ 40% of the total lung volume receives ≥ 20 Gy of radiotherapy
• Previously untreated disease OR achieved stable disease or partial response within 8 weeks after completion of 2-6 courses of standard platinum-based chemotherapy (administered every 3-4 weeks)
• Pleural effusion allowed provided it is minimal
• No history of or current brain metastases
• * Patients who have had up to 3 brain metastases allowed provided they have been treated with not signs of progression
• PATIENT CHARACTERISTICS:
• ECOG performance status 0-1
• Life expectancy ≥ 12 weeks
• Platelet count ≥ 100,00/mm\^3
• Hemoglobin ≥ 9 g/dL
• WBC ≥ 2,000/mm\^3
• Creatinine ≤ 2 times upper limit of normal
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception
• Able to undergo radiotherapy, based on radiation oncology consultation
• Willing and able to comply with study treatment
• FEV\_1 ≥ 1 L
• No requirement for daily supplemental oxygen
• No second primary malignancy, except for any of the following:
• * Carcinoma in situ of the cervix
• * Nonmelanoma skin cancer
• * History of low-grade (Gleason score ≤ 6) localized prostate cancer, even if diagnosed within the past 5 years
• * Stage I breast cancer that was treated within the past 5 years
• * Other malignancy that was diagnosed and definitely treated ≥ 5 years ago with no subsequent evidence of recurrence
• No concurrent severe and/or uncontrolled medical condition, including any of the following:
• * Angina pectoris
• * Congestive heart failure within the past 3 months, unless LVEF \> 40%
• * Myocardial infarction within the past 6 months
• * Cardiac arrhythmia
• No clinically significant infection
• No psychiatric illness or social situation that would limit compliance with study requirements
• PRIOR CONCURRENT THERAPY:
• See Disease Characteristics
• No prior therapy for this cancer other than 2-6 courses of standard platinum-based chemotherapy with or without bevacizumab
• No prior radiotherapy to the treatment sites (e.g., primary lesion, clinically involved nodes, or metastatic lesions)
• No bevacizumab during and for 4 weeks after completion of radiotherapy
• No concurrent systemic chemotherapy
• No other maintenance systemic therapy during radiotherapy
• No other concurrent investigational agents for the primary neoplasm
• No concurrent intensity modulated radiotherapy
• No concurrent prophylactic nodal radiotherapy